Hepatitis C virus core and E2 protein expression in transgenic mice

Area of Science:

• Hepatology
• Virology
• Transgenic Animal Models

Background:

• Hepatitis C virus (HCV) infection poses a significant global health challenge.
• The cytopathic effects of HCV core and E2 proteins in vivo remain incompletely understood.
• Previous in vitro studies suggested potential oncogenic roles for HCV proteins.

Purpose of the Study:

• To generate and characterize transgenic mouse models expressing HCV core and E2 proteins in the liver.
• To evaluate the in vivo cytopathic effects and oncogenic potential of these viral proteins.
• To investigate the interaction of HCV core protein with hepatitis B virus (HBV) replication in a co-infection model.

Main Methods:

• Generation of transgenic mice expressing full-length HCV core protein under the mouse major urinary protein promoter.
• Generation of transgenic mice expressing a truncated HCV E2 protein under the mouse albumin promoter.
• Assessment of liver histology, biochemistry, and viral gene expression in transgenic animals.

Main Results:

• Transgenic mice expressed HCV core protein in hepatocytes at levels comparable to infected patients, without signs of liver disease or hepatocellular carcinoma.
• Co-expression of HCV core protein with HBV in double transgenic mice did not inhibit HBV gene expression or replication.
• High-level expression of truncated HCV E2 protein in transgenic mice did not induce liver disease.

Conclusions:

• HCV core and E2 proteins are not cytopathic to hepatocytes in vivo.
• These findings challenge previous in vitro observations regarding the oncogenic potential of HCV proteins.
• The developed transgenic models represent a valuable tool for studying HCV immunopathology in vivo.